NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
Clinical Trials
34 trialsNCT06137170 2026-03-02
RegoSeq
Bayer
Completed
NCT05198934 2026-02-06
CodeBreak300
Amgen
Phase 3 Active not recruiting
NCT04776148 2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03377361 2025-12-03
CheckMate 9N9
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05839951 2025-11-12
STAR-T
Bayer
Completed
NCT04660812 2025-10-20
ARC-9
Arcus Biosciences, Inc.
Phase 1/2 Completed
NCT05064059 2025-09-17
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07134205 2025-08-21
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
NCT05328908 2025-08-13
RELATIVITY-123
Bristol-Myers Squibb
Phase 3 Terminated
NCT06029010 2025-02-26
COLONGER
Bayer
Completed
NCT03563157 2024-12-11
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03564938 2024-12-03
Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).
Bayer
Phase 4 Completed
NCT04701476 2024-11-22
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Teclison Ltd.
Phase 2 Recruiting
NCT03890731 2024-04-02
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
Bayer
Phase 2 Completed
NCT06089330 2023-10-18
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
Phase 2 Unknown
NCT02106858 2023-07-24
StivargaPMS
Bayer
Completed
NCT04126733 2023-07-18
Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
Bayer
Phase 2 Completed
NCT05130021 2021-12-06
A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer
Maxinovel Pty., Ltd.
Phase 2 Unknown
NCT03081494 2020-12-11
Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer
Novartis
Phase 1 Completed
NCT02425683 2020-02-10
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
US Oncology Research
Phase 2 Terminated
NCT02788279 2019-12-11
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
Hoffmann-La Roche
Phase 3 Completed
NCT01538680 2019-05-29
CONSIGN
Bayer
No longer available
NCT01853319 2019-04-22
REGARD
Bayer
Phase 3 Completed
NCT02465502 2018-11-07
Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer
Bayer
Phase 2 Completed
NCT02347852 2018-09-10
REGO-ACT
Bayer
Completed
NCT01843400 2018-08-02
Regorafenib Post-marketing Surveillance
Bayer
Completed
NCT03386825 2018-05-15
COLONG
Bayer
Completed
NCT02656524 2018-02-12
Stivarga Real Life Evidence in Hungary
Bayer
Completed
NCT02042144 2018-01-16
Correlate
Bayer
Completed
NCT01939223 2017-10-20
COAST
Bayer
Phase 3 Terminated
NCT01584830 2016-02-08
CONCUR
Bayer
Phase 3 Completed
NCT01103323 2015-06-24
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Bayer
Phase 3 Completed
NCT00934882 2014-06-02
Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI
Bayer
Phase 1 Completed